Skip to main content
. 2021 Jan 8;12(2):66–71. doi: 10.4103/picr.PICR_138_20

Figure 4.

Figure 4

Adaptive trial design. All eligible patients are randomized to Placebo (p) or treatment Groups A, B, C or D. Interim analysis is run at defined time points and any treatment arm with low probability of benefit or potential harm is subjected to dose modification accordingly. A newly discovered treatment (e) can be added at later stage if required